ArticleScientific reports2025
MMP14 and DDR2 are potential molecular markers for metastatic triple-negative breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Review
- Bioactive Natural Compounds in Triple-Negative Breast Cancer: Molecular Targets and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Emerging Protein Targets in Triple-Negative Breast Cancer: Beyond Conventional Therapy.Cancers · 2026Review
- Bioinformatic Analysis of Contrasting Expression Patterns and Molecular Interactions of TIMPs in Breast Cancer: Implications for Tumor Progression and Survival.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Decoding collagen cues: the interplay of integrins and discoidin domain receptors in health and disease.Journal of biomedical science · 2026Review
- Molecular markers in triple-negative breast cancer: A retrospective correlation study.Bioinformation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is one of the most aggressive and rapidly invasive breast cancer types. TNBC's potential to metastasize is greater than other types of breast cancer, and current research aims at finding distinct molecular targets that may serve as potential targeted therapeutics. Here, we utilized TNBC tissue microarrays to determine the protein expression of seven matrix metalloproteinases (MMPs) and Discoidin domain receptor 2 (DDR2) in metastatic and non-metastatic TNBC to identify potential targets for immunotherapy. We found MMP1 expression inversely correlated with tumor grade, whereas MMP2, 3, 12, and 13 expression directly correlated with tumor grade (p < 0.05). Metastatic TNBC correlated with the expression of DDR2 (r = 0.231, p = 0.043), MMP11 (r = 0.272, p = 0.017), and MMP14 (r = 0.426, p < 0.001). Multi-marker models were tested for their potential to predict metastatic TNBC from non-metastatic TNBC. An all-marker model had a significant classification potential (odd ratio (OR) 23.44 (95%CI: 6.06-73.1), p < 0.0001), whereas a 3-marker model that included DDR2, MMP2, and MMP14 had similar significant classification (OR 19.4 (5.1-60.4), p < 0.0001). Moreover, model performance metrics were comparable for the two models. Therefore, we propose MMP14 and DDR2 as potential molecular markers for the detection of metastatic TNBC. In addition, further research on the efficacy of targeted dual immunotherapies against MMP14 and DDR2 in TNBC is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.